Seroresponse to SARS-CoV-2 Vaccines Among Maintenance Dialysis Patients

  1. Caroline M. Hsu
  2. Daniel E. Weiner
  3. Gideon N. Aweh
  4. Harold J. Manley
  5. Vladimir Ladik
  6. Jill Frament
  7. Dana Miskulin
  8. Christos Argyropoulos
  9. Kenneth Abreo
  10. Andrew Chin
  11. Reginald Gladish
  12. Loay Salman
  13. Doug Johnson
  14. Eduardo K. Lacson

Reviewed by

Read the full article

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1053/j.ajkd.2021.10.002
  2. ScreenIT

    SciScore for 10.1101/2021.08.19.21262292: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Ethicsnot detected.
    Sex as a biological variablenot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.

    Table 2: Resources

    Software and Algorithms
    SentencesResources
    Statistical analyses were performed using SAS v9.4.
    SAS
    suggested: (SASqPCR, RRID:SCR_003056)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    Our study has its limitations. In this observational retrospective study, some confounders may not have been accounted for. The comparison of maximum to initial SAb-IgG titers is limited by the patients who only had one titer checked between 14 and 74 days. Lastly, as noted, while the assessment of SAb-IgG titer at least 14 days after completion of vaccine series corresponds with the current definition of “fully vaccinated,”11 it creates a difference in timing relative to the initial dose between one-dose and two-dose regimens. In conclusion, mRNA vaccines are associated with greater seroresponse in maintenance dialysis patients, and they should continue to be widely used to protect this vulnerable population. Further study is needed to monitor the durability of this seroresponse. In addition, further investigation should evaluate the role of the Ad26.COV2.S/Janssen vaccine in this population, and repeat dosing may be needed.

    Results from TrialIdentifier: We found the following clinical trial numbers in your paper:

    IdentifierStatusTitle
    NCT04614948Active, not recruitingA Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-medi…

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    Results from scite Reference Check: We found no unreliable references.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2021.08.19.21262292v1 on medRxiv